GlassScriptPhysician profile
Oumitana Kajkenova
NPI 1053401521
$4,838.49
in general payments reported to CMS, 2019-2025
37 companies · $1,019 in 2025
The $1,019 reported for 2025 was more than what 89% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
See the full distribution for Geriatric Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,103 · 2020: $261 · 2021: $527 · 2022: $503 · 2023: $759 · 2024: $666 · 2025: $1,019.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,328 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,327.91 |
| Education | $116.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $615.96 | 2023-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $572.26 | 2019-2024 | |
| Amgen INC. | $502.61 | 2019-2025 | Tavneos, Otezla, Repatha |
| Pfizer INC. | $347.27 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $282.56 | 2019-2025 | Spravato |
| Eisai INC. | $276.33 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $247.96 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $235.06 | 2024-2025 | Austedo Xr, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $186.35 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $173.69 | 2023-2024 | Ingrezza |
| Lundbeck LLC | $162.97 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $160.05 | 2022-2025 | Kisunla, Mounjaro, Amyvid |
| Sumitomo Pharma America, INC. | $114.45 | 2023 | Gemtesa |
| Biogen, INC. | $113.81 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $111.62 | 2023 | Quviviq |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oumitana Kajkenova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.